Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight Inc. has demonstrated a positive financial trajectory, with its third-quarter revenue surpassing consensus expectations and management increasing the guidance midpoint, indicating robust business growth. The company has also revised its gross margin guidance upward to 76-77%, reflecting improved efficiencies and a favorable product mix, particularly from higher-margin light adjustable lenses (LALs). Additionally, strategic initiatives aimed at enhancing engagement and driving volume growth for LDD placements are expected to contribute to further improvements in both revenue and margins, positioning RxSight positively within the medical technology sector.

Bears say

RxSight Inc. has experienced a decline in LAL (Light Adjustable Lens) utilization, with monthly usage falling to 8.0 LALs per LDD in 3Q25, down from 8.7 in 2Q25 and 10.1 in 3Q24, indicating potential challenges in customer adoption or market penetration. The company's revenue for 3Q25 was reported at $30.3 million, reflecting a year-over-year decrease of 14%, and management has projected FY2026 revenue to be between $120 million and $135 million, which is below prior estimates and indicates a potential contraction of 11% year-over-year. Furthermore, RxSight anticipates that gross margins will face pressure from higher-cost inventory starting in 2Q26, signaling further financial strain as the company grapples with both declining revenues and increasing operational costs.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.